HEPA: Hepion Pharmaceuticals, Inc. Stock

by  •  • Comments Off on HEPA: Hepion Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 8.10
Enterprise Value ($M) -4.99
Book Value ($M) 7.28
Book Value / Share 1.33
Price / Book 1.11
NCAV ($M) 6.67
NCAV / Share 1.22
Price / NCAV 1.21

Profitability (mra)
Return on Invested Capital (ROIC) -6.53
Return on Assets (ROA) -0.99
Return on Equity (ROE) -1.32

Liquidity (mrq)
Quick Ratio 3.31
Current Ratio 3.31

Balance Sheet (mrq) ($M)
Current Assets 17.49
Assets 18.09
Liabilities 10.81
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -45.26
Net Income -48.93
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -40.89
Cash from Investing -0.01
Cash from Financing 4.49

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 8.67

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-16 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 O
2023-11-20 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 o TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 o TRANSITION REPORT PURSUANT TO S
2023-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 o TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-24 10,540 6,553 160.84
2024-04-23 19,206 20,237 94.91
2024-04-22 96,289 45,276 212.67
2024-04-19 9,930 16,629 59.71

(click for more detail)

Similar Companies
GOVX – GeoVax Labs, Inc. GTBP – GT Biopharma, Inc.
GYRE – Gyre Therapeutics, Inc. HOOK – HOOKIPA Pharma Inc.
HOTH – Hoth Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io